Sangamo Biosciences (SGMO) 6.44 $SGMO
Global Thalassemia Market Report: 2016 Edition - Gene Therapy for Curing Thalassemia/ Advances in Iron Chelation Therapy / Fetal Hemoglobin Inducers - Research and Markets
BusinessWire - Fri Jun 10, 4:19AM CDT
Research and Markets has announced the addition of the "Global Thalassemia Market Report: 2016 Edition" report to their offering.
SGMO: 6.44 (-0.31)
Sangamo BioSciences Announces Presentation at the Jefferies 2016 Healthcare Conference
PR Newswire - Wed Jun 01, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Edward Lanphier, Sangamo's founder and former president and chief executive officer, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 8:30 am ET on Wednesday, June 8, 2016, at the Jefferies 2016 Healthcare Conference. Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's newly appointed president and chief executive officer will also be attending the conference, which is being held in New York from June 7-10, 2016.
SGMO: 6.44 (-0.31)
Sangamo BioSciences Announces Retirement Of Edward Lanphier As President And CEO; Sandy Macrae Named As Successor
PR Newswire - Wed Jun 01, 6:00AM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today announced the company has appointed Alexander 'Sandy' Macrae, M.B., Ch.B, Ph.D., MRCP, as president and chief executive officer to succeed current president and CEO, Edward Lanphier. Mr. Lanphier is retiring from the day-to-day leadership of Sangamo. He will continue as a member of the board of directors and, as previously disclosed, will assume the chairmanship of the board immediately following the 2016 annual meeting of stockholders which will be held on June 14, 2016. Mr. William Ringo, Sangamo's current chairman since 2010, will remain on the board as chairman of the Nominating and Governance Committee and member of the Compensation Committee. Dr. Macrae has assumed the CEO role effective today.
SGMO: 6.44 (-0.31)
Sangamo BioSciences Announces Participation At Upcoming Investor Conferences
PR Newswire - Tue May 10, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Edward Lanphier, Sangamo's president and chief executive officer, will participate in the following upcoming conferences.
SGMO: 6.44 (-0.31)
Sangamo BioSciences Reports First Quarter 2016 Financial Results
PR Newswire - Mon May 02, 3:05PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today reported its first quarter 2016 financial results and accomplishments.
SGMO: 6.44 (-0.31)
Sangamo BioSciences Announces Presentation At The Deutsche Bank 41st Annual Health Care Conference
PR Newswire - Thu Apr 28, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Edward Lanphier, Sangamo's president and chief executive officer, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 9:20 am ET on Thursday, May 5, 2016, at the Deutsche Bank 41st Annual Health Care Conference. The conference is being held in Boston from May 4-5, 2016.
SGMO: 6.44 (-0.31), DB: 15.74 (-0.97)
Sangamo BioSciences Announces First Quarter 2016 Conference Call and Webcast
PR Newswire - Mon Apr 25, 3:03PM CDT
Sangamo BioSciences, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, today announced that the company will release its first quarter 2016 financial results after the market closes on Monday, May 2, 2016. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the quarter's financial results and discuss other business matters.
SGMO: 6.44 (-0.31)
Sangamo BioSciences Announces Presentations On ZFP Therapeutic® Programs And Applications At 2016 Annual Meeting Of The American Society Of Gene & Cell Therapy
PR Newswire - Mon Apr 18, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced that data from several ZFP Therapeutic programs will be presented at the 19th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) to be held in Washington, D.C. from May 4-7, 2016.
SGMO: 6.44 (-0.31)
Why Investors Are So Bullish on This Small Biotech
ACCESSWIRE - Wed Mar 30, 9:30AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.
ESPR: 16.74 (-1.01), CMRX: 4.14 (-0.44), GERN: 2.77 (-0.04), CYTX: 2.27 (-0.01), CLDX: 4.12 (-0.20), SGMO: 6.44 (-0.31), PTCT: 7.24 (-0.30), ATHX: 2.38 (+0.03), MNKD: 1.01 (-0.02)
Sangamo BioSciences Announces Participation In The 4th Annual Cell & Gene Therapy Investor Day Meeting In New York
PR Newswire - Tue Mar 15, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that Elizabeth Wolffe, Ph.D., Sangamo's vice president, corporate communications, will present an overview of the Company's ZFP Therapeutic® programs at 11:15am ET on Tuesday, March 22, 2016, at the 4th Annual Cell & Gene Therapy Investor Day. The meeting will be held in New York City.
SGMO: 6.44 (-0.31)
Biotech Trade Alert
ACCESSWIRE - Tue Mar 15, 11:50AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 15, 2016 / We are issuing an immediate trade alert on Endonovo Therapeutics (OTCQB: ENDV) and a few other biotech companies.
ESPR: 16.74 (-1.01), VCEL: 2.43 (-0.07), SGMO: 6.44 (-0.31), ZYNE: 8.77 (-0.28)
Sangamo BioSciences Reports Fourth Quarter And Full Year 2015 Financial Results
PR Newswire - Tue Feb 09, 3:03PM CST
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today reported its fourth quarter and full year 2015 financial results and accomplishments.
SGMO: 6.44 (-0.31)
Shares of SGMO Down 24.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 05, 6:42PM CST
SmarTrend identified a Downtrend for Sangamo Biosciences (NASDAQ:SGMO) on January 8th, 2016 at $7.70. In approximately 4 weeks, Sangamo Biosciences has returned 24.89% as of today's recent price of $5.78.
SGMO: 6.44 (-0.31)
Sangamo BioSciences Announces Presentation At The Leerink Partners 5th Annual Global Healthcare Conference
PR Newswire - Thu Feb 04, 3:03PM CST
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Edward Lanphier, Sangamo's president and chief executive officer, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 2:40 pm ET on Thursday, February 11, 2016, at the Leerink Partners 5th Annual Global Healthcare Conference. The conference is being held in New York.
SGMO: 6.44 (-0.31)
Sickle Cell Disease Pipeline Review, H2 2015
M2 - Wed Feb 03, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/44gnx8/sickle_cell) has announced the addition of the "Sickle Cell Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sickle Cell Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sickle Cell Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Sickle Cell Disease Overview - Therapeutics Development - Pipeline Products for Sickle Cell Disease - Overview - Pipeline Products for Sickle Cell Disease - Comparative Analysis - Sickle Cell Disease - Therapeutics under Development by Companies - Sickle Cell Disease - Therapeutics under Investigation by Universities/Institutes - Sickle Cell Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Sickle Cell Disease - Products under Development by Companies - Sickle Cell Disease - Products under Investigation by Universities/Institutes - Sickle Cell Disease - Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Alnylam Pharmaceuticals, Inc. - Bluebird bio, Inc. - Bristol-Myers Squibb Company - Complexa, Inc. - Daiichi Sankyo Company, Limited - Dilaforette AB - Emmaus Medical, Inc. - Errant Gene Therapeutics, LLC - Gamida Cell Ltd. - Gilead Sciences, Inc. - Global Blood Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Johnson & Johnson - La Jolla Pharmaceutical Company - Morphogenesis, Inc. - NKT Therapeutics, Inc. - Novartis AG - Orphagen Pharmaceuticals, Inc. - Pfizer Inc. - PharmaEssentia Corporation - Prolong Pharmaceuticals - ReveraGen BioPharma, Inc. - Sancilio & Company, Inc. - Sangamo BioSciences, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/44...ickle_cell
JNJ: 117.01 (+0.01), GBT: 24.15 (+2.00), ISIS: 57.56 (-0.28), GILD: 84.45 (-1.32), PFE: 35.29 (-0.02), SGMO: 6.44 (-0.31), BMY: 72.65 (-0.08), NVS: 78.94 (-1.57), XLRN: 35.44 (+0.94)
Sangamo BioSciences Announces Fourth Quarter And Full Year 2015 Conference Call And Webcast
PR Newswire - Tue Feb 02, 3:03PM CST
Sangamo BioSciences, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, today announced that the company will release its fourth quarter and full year 2015 financial results after the market closes on Tuesday, February 9, 2016. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the quarter's financial results and discuss other business matters.
SGMO: 6.44 (-0.31)
The Alliance for Regenerative Medicine Announces Fourth Annual Cell & Gene Therapy Investor Day & Initial Slate of Presenting Companies
Marketwired - Tue Feb 02, 8:02AM CST
The Alliance for Regenerative Medicine (ARM) today announced its annual Cell & Gene Therapy Investor Day will take place March 22, 2016 in New York City. The event is co-hosted by leading investment banking firm Piper Jaffray.
SGMO: 6.44 (-0.31)
Weird Science: 4 Healthcare And Medical Device Companies Developing Futuristic Technologies In 2016
ACCESSWIRE - Fri Jan 29, 6:50PM CST
WINDSOR, ON / ACCESSWIRE / January 29, 2016 / The Wealthy Biotech Trader (or "WBT"
, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharmaceutical and medical device stocks releasing impressive news and making market moves, has developed a list of stocks skirting the boundaries of reality which could make a big contribution to healthcare innovation in 2016 and beyond.
EYES: 4.03 (-0.68), SGMO: 6.44 (-0.31)
16.4% Return Seen to Date on SmarTrend Sangamo Biosciences Call (SGMO)
Comtex SmarTrend(R) - Fri Jan 29, 10:20AM CST
SmarTrend identified a Downtrend for Sangamo Biosciences (NASDAQ:SGMO) on January 8th, 2016 at $7.70. In approximately 3 weeks, Sangamo Biosciences has returned 16.44% as of today's recent price of $6.43.
SGMO: 6.44 (-0.31)
Hemophilia A Therapeutics Pipeline Review 2015
M2 - Fri Jan 22, 6:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/5rtzx4/hemophilia_a) has announced the addition of the "Hemophilia A - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hemophilia A, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia A and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hemophilia A Overview - Therapeutics Development - Pipeline Products for Hemophilia A - Overview - Pipeline Products for Hemophilia A - Comparative Analysis - Hemophilia A - Therapeutics under Development by Companies - Hemophilia A - Therapeutics under Investigation by Universities/Institutes - Hemophilia A - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hemophilia A - Products under Development by Companies - Hemophilia A - Products under Investigation by Universities/Institutes - Hemophilia A - Companies Involved in Therapeutics Development - Alnylam Pharmaceuticals, Inc. - Amarna Therapeutics B.V. - Apitope International NV - AstraZeneca Plc - Baxalta Incorporated - Bayer AG - Biogen, Inc. - BioMarin Pharmaceutical Inc. - Catalyst Biosciences, Inc. - Celtic Pharmaceutical Holdings L.P. - CSL Limited - DBV Technologies S.A. - Dimension Therapeutics, Inc. - Dong-A Socio Group - Emergent BioSolutions Inc. - EpiVax, Inc. - Expression Therapeutics LLC - F. Hoffmann-La Roche Ltd. - Green Cross Corporation - Inbiopro Solutions Pvt. Ltd. - Lentigen Technology, Inc. - mAbxience S.A. - Novo Nordisk A/S - OPKO Health, Inc. - Pfizer Inc. - Pharming Group N.V. - rEVO Biologics, Inc. - Sangamo BioSciences, Inc. - Selecta Biosciences, Inc. - SK Chemicals Co., Ltd. - Spark Therapeutics, Inc. - The International Biotechnology Center (IBC) Generium - uniQure N.V. For more information visit http://www.researchandmarkets.com/research/5r...mophilia_a
BMRN: 81.10 (-1.84), EBS: 42.30 (-1.19), PFE: 35.29 (-0.02), SGMO: 6.44 (-0.31), RBIO: (), DMTX: 10.15 (+0.08), NVO: 55.36 (-1.51), OPK: 9.30 (-0.31), ONCE: 53.58 (+0.03), AZN: 27.97 (-0.99), CBIO: 1.81 (-0.07), BXLT: 46.02 (-0.18)
Global Thalassemia Market Report: 2016 Edition - Gene Therapy for Curing Thalassemia/ Advances in Iron Chelation Therapy / Fetal Hemoglobin Inducers - Research and Markets
BusinessWire - Fri Jun 10, 4:19AM CDT
Research and Markets has announced the addition of the "Global Thalassemia Market Report: 2016 Edition" report to their offering.
SGMO: 6.44 (-0.31)
Sangamo BioSciences Announces Presentation at the Jefferies 2016 Healthcare Conference
PR Newswire - Wed Jun 01, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Edward Lanphier, Sangamo's founder and former president and chief executive officer, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 8:30 am ET on Wednesday, June 8, 2016, at the Jefferies 2016 Healthcare Conference. Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's newly appointed president and chief executive officer will also be attending the conference, which is being held in New York from June 7-10, 2016.
SGMO: 6.44 (-0.31)
Sangamo BioSciences Announces Retirement Of Edward Lanphier As President And CEO; Sandy Macrae Named As Successor
PR Newswire - Wed Jun 01, 6:00AM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today announced the company has appointed Alexander 'Sandy' Macrae, M.B., Ch.B, Ph.D., MRCP, as president and chief executive officer to succeed current president and CEO, Edward Lanphier. Mr. Lanphier is retiring from the day-to-day leadership of Sangamo. He will continue as a member of the board of directors and, as previously disclosed, will assume the chairmanship of the board immediately following the 2016 annual meeting of stockholders which will be held on June 14, 2016. Mr. William Ringo, Sangamo's current chairman since 2010, will remain on the board as chairman of the Nominating and Governance Committee and member of the Compensation Committee. Dr. Macrae has assumed the CEO role effective today.
SGMO: 6.44 (-0.31)
Sangamo BioSciences Announces Participation At Upcoming Investor Conferences
PR Newswire - Tue May 10, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Edward Lanphier, Sangamo's president and chief executive officer, will participate in the following upcoming conferences.
SGMO: 6.44 (-0.31)
Sangamo BioSciences Reports First Quarter 2016 Financial Results
PR Newswire - Mon May 02, 3:05PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today reported its first quarter 2016 financial results and accomplishments.
SGMO: 6.44 (-0.31)
Sangamo BioSciences Announces Presentation At The Deutsche Bank 41st Annual Health Care Conference
PR Newswire - Thu Apr 28, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Edward Lanphier, Sangamo's president and chief executive officer, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 9:20 am ET on Thursday, May 5, 2016, at the Deutsche Bank 41st Annual Health Care Conference. The conference is being held in Boston from May 4-5, 2016.
SGMO: 6.44 (-0.31), DB: 15.74 (-0.97)
Sangamo BioSciences Announces First Quarter 2016 Conference Call and Webcast
PR Newswire - Mon Apr 25, 3:03PM CDT
Sangamo BioSciences, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, today announced that the company will release its first quarter 2016 financial results after the market closes on Monday, May 2, 2016. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the quarter's financial results and discuss other business matters.
SGMO: 6.44 (-0.31)
Sangamo BioSciences Announces Presentations On ZFP Therapeutic® Programs And Applications At 2016 Annual Meeting Of The American Society Of Gene & Cell Therapy
PR Newswire - Mon Apr 18, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced that data from several ZFP Therapeutic programs will be presented at the 19th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) to be held in Washington, D.C. from May 4-7, 2016.
SGMO: 6.44 (-0.31)
Why Investors Are So Bullish on This Small Biotech
ACCESSWIRE - Wed Mar 30, 9:30AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.
ESPR: 16.74 (-1.01), CMRX: 4.14 (-0.44), GERN: 2.77 (-0.04), CYTX: 2.27 (-0.01), CLDX: 4.12 (-0.20), SGMO: 6.44 (-0.31), PTCT: 7.24 (-0.30), ATHX: 2.38 (+0.03), MNKD: 1.01 (-0.02)
Sangamo BioSciences Announces Participation In The 4th Annual Cell & Gene Therapy Investor Day Meeting In New York
PR Newswire - Tue Mar 15, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that Elizabeth Wolffe, Ph.D., Sangamo's vice president, corporate communications, will present an overview of the Company's ZFP Therapeutic® programs at 11:15am ET on Tuesday, March 22, 2016, at the 4th Annual Cell & Gene Therapy Investor Day. The meeting will be held in New York City.
SGMO: 6.44 (-0.31)
Biotech Trade Alert
ACCESSWIRE - Tue Mar 15, 11:50AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 15, 2016 / We are issuing an immediate trade alert on Endonovo Therapeutics (OTCQB: ENDV) and a few other biotech companies.
ESPR: 16.74 (-1.01), VCEL: 2.43 (-0.07), SGMO: 6.44 (-0.31), ZYNE: 8.77 (-0.28)
Sangamo BioSciences Reports Fourth Quarter And Full Year 2015 Financial Results
PR Newswire - Tue Feb 09, 3:03PM CST
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today reported its fourth quarter and full year 2015 financial results and accomplishments.
SGMO: 6.44 (-0.31)
Shares of SGMO Down 24.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 05, 6:42PM CST
SmarTrend identified a Downtrend for Sangamo Biosciences (NASDAQ:SGMO) on January 8th, 2016 at $7.70. In approximately 4 weeks, Sangamo Biosciences has returned 24.89% as of today's recent price of $5.78.
SGMO: 6.44 (-0.31)
Sangamo BioSciences Announces Presentation At The Leerink Partners 5th Annual Global Healthcare Conference
PR Newswire - Thu Feb 04, 3:03PM CST
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Edward Lanphier, Sangamo's president and chief executive officer, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 2:40 pm ET on Thursday, February 11, 2016, at the Leerink Partners 5th Annual Global Healthcare Conference. The conference is being held in New York.
SGMO: 6.44 (-0.31)
Sickle Cell Disease Pipeline Review, H2 2015
M2 - Wed Feb 03, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/44gnx8/sickle_cell) has announced the addition of the "Sickle Cell Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sickle Cell Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sickle Cell Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Sickle Cell Disease Overview - Therapeutics Development - Pipeline Products for Sickle Cell Disease - Overview - Pipeline Products for Sickle Cell Disease - Comparative Analysis - Sickle Cell Disease - Therapeutics under Development by Companies - Sickle Cell Disease - Therapeutics under Investigation by Universities/Institutes - Sickle Cell Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Sickle Cell Disease - Products under Development by Companies - Sickle Cell Disease - Products under Investigation by Universities/Institutes - Sickle Cell Disease - Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Alnylam Pharmaceuticals, Inc. - Bluebird bio, Inc. - Bristol-Myers Squibb Company - Complexa, Inc. - Daiichi Sankyo Company, Limited - Dilaforette AB - Emmaus Medical, Inc. - Errant Gene Therapeutics, LLC - Gamida Cell Ltd. - Gilead Sciences, Inc. - Global Blood Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Johnson & Johnson - La Jolla Pharmaceutical Company - Morphogenesis, Inc. - NKT Therapeutics, Inc. - Novartis AG - Orphagen Pharmaceuticals, Inc. - Pfizer Inc. - PharmaEssentia Corporation - Prolong Pharmaceuticals - ReveraGen BioPharma, Inc. - Sancilio & Company, Inc. - Sangamo BioSciences, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/44...ickle_cell
JNJ: 117.01 (+0.01), GBT: 24.15 (+2.00), ISIS: 57.56 (-0.28), GILD: 84.45 (-1.32), PFE: 35.29 (-0.02), SGMO: 6.44 (-0.31), BMY: 72.65 (-0.08), NVS: 78.94 (-1.57), XLRN: 35.44 (+0.94)
Sangamo BioSciences Announces Fourth Quarter And Full Year 2015 Conference Call And Webcast
PR Newswire - Tue Feb 02, 3:03PM CST
Sangamo BioSciences, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, today announced that the company will release its fourth quarter and full year 2015 financial results after the market closes on Tuesday, February 9, 2016. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the quarter's financial results and discuss other business matters.
SGMO: 6.44 (-0.31)
The Alliance for Regenerative Medicine Announces Fourth Annual Cell & Gene Therapy Investor Day & Initial Slate of Presenting Companies
Marketwired - Tue Feb 02, 8:02AM CST
The Alliance for Regenerative Medicine (ARM) today announced its annual Cell & Gene Therapy Investor Day will take place March 22, 2016 in New York City. The event is co-hosted by leading investment banking firm Piper Jaffray.
SGMO: 6.44 (-0.31)
Weird Science: 4 Healthcare And Medical Device Companies Developing Futuristic Technologies In 2016
ACCESSWIRE - Fri Jan 29, 6:50PM CST
WINDSOR, ON / ACCESSWIRE / January 29, 2016 / The Wealthy Biotech Trader (or "WBT"
, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharmaceutical and medical device stocks releasing impressive news and making market moves, has developed a list of stocks skirting the boundaries of reality which could make a big contribution to healthcare innovation in 2016 and beyond. EYES: 4.03 (-0.68), SGMO: 6.44 (-0.31)
16.4% Return Seen to Date on SmarTrend Sangamo Biosciences Call (SGMO)
Comtex SmarTrend(R) - Fri Jan 29, 10:20AM CST
SmarTrend identified a Downtrend for Sangamo Biosciences (NASDAQ:SGMO) on January 8th, 2016 at $7.70. In approximately 3 weeks, Sangamo Biosciences has returned 16.44% as of today's recent price of $6.43.
SGMO: 6.44 (-0.31)
Hemophilia A Therapeutics Pipeline Review 2015
M2 - Fri Jan 22, 6:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/5rtzx4/hemophilia_a) has announced the addition of the "Hemophilia A - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hemophilia A, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia A and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hemophilia A Overview - Therapeutics Development - Pipeline Products for Hemophilia A - Overview - Pipeline Products for Hemophilia A - Comparative Analysis - Hemophilia A - Therapeutics under Development by Companies - Hemophilia A - Therapeutics under Investigation by Universities/Institutes - Hemophilia A - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hemophilia A - Products under Development by Companies - Hemophilia A - Products under Investigation by Universities/Institutes - Hemophilia A - Companies Involved in Therapeutics Development - Alnylam Pharmaceuticals, Inc. - Amarna Therapeutics B.V. - Apitope International NV - AstraZeneca Plc - Baxalta Incorporated - Bayer AG - Biogen, Inc. - BioMarin Pharmaceutical Inc. - Catalyst Biosciences, Inc. - Celtic Pharmaceutical Holdings L.P. - CSL Limited - DBV Technologies S.A. - Dimension Therapeutics, Inc. - Dong-A Socio Group - Emergent BioSolutions Inc. - EpiVax, Inc. - Expression Therapeutics LLC - F. Hoffmann-La Roche Ltd. - Green Cross Corporation - Inbiopro Solutions Pvt. Ltd. - Lentigen Technology, Inc. - mAbxience S.A. - Novo Nordisk A/S - OPKO Health, Inc. - Pfizer Inc. - Pharming Group N.V. - rEVO Biologics, Inc. - Sangamo BioSciences, Inc. - Selecta Biosciences, Inc. - SK Chemicals Co., Ltd. - Spark Therapeutics, Inc. - The International Biotechnology Center (IBC) Generium - uniQure N.V. For more information visit http://www.researchandmarkets.com/research/5r...mophilia_a
BMRN: 81.10 (-1.84), EBS: 42.30 (-1.19), PFE: 35.29 (-0.02), SGMO: 6.44 (-0.31), RBIO: (), DMTX: 10.15 (+0.08), NVO: 55.36 (-1.51), OPK: 9.30 (-0.31), ONCE: 53.58 (+0.03), AZN: 27.97 (-0.99), CBIO: 1.81 (-0.07), BXLT: 46.02 (-0.18)
